Actions extend debt maturities, preserve financial flexibility and support growth opportunities Raised additional $700 million liquidity through new 3-year term loan and expansion of existing revolving credit facility Additional liquidity supports near-term tungsten related working capital needs while preserving long-term flexibility Refinanced $300 million in bonds, extending maturities to 2036, as previously reported Transactions consistent with maintained investment grade credit rating profile PITTSBURGH, May 29, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced a series of financing transactions designed to enhance liquidity, extend debt maturities and position the Company to capture near-term growth opportunities. The actions provide additional financial flexibility to support near-term tungsten related working capital needs while preserving flexibility to respond to future market developments.

PITTSBURGH, May 27, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced the final results and expiration of its previously announced cash tender offer (the "Tender Offer") to purchase any and all of the outstanding notes listed in the table below (the "Notes"). Capitalized terms used in this news release and not defined herein have the meanings given to them in the Offer to Purchase, dated May 19, 2026 (the "Offer to Purchase").

PITTSBURGH, May 26, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced the pricing terms of its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its outstanding 4.625% Senior Notes due 2028 (the "2028 Notes"). All other terms and conditions of the Tender Offer remain unchanged and are described in the Offer to Purchase, dated May 19, 2026 (the "Offer to Purchase").

PITTSBURGH, May 19, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced that it has commenced an underwritten public offering of senior notes (the "Notes Offering"). The exact amount and terms of the Notes Offering will depend upon market conditions and other factors.

PITTSBURGH, May 18, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference in Boston. Details of the conference are as follows: When:   Wednesday, May 27, 2026   Attendees: Sanjay Chowbey, President and Chief Executive Officer Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.

Sales of $593 million increased 22 percent and 19 percent on a reported and organic basis, respectively Operating income of $79 million and adjusted operating income of $82 million, up 80 percent and 64 percent, respectively Earnings per diluted share (EPS) of $0.75 and adjusted EPS of $0.77, up 85 percent and 65 percent, respectively Company raises annual sales and adjusted EPS Outlook PITTSBURGH, May 6, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today reported results for its fiscal 2026 third quarter ended March 31, 2026. "Our third quarter results exceeded the high end of our sales and adjusted EPS Outlook, primarily due to the unprecedented rise in tungsten pricing and stronger volume," said Sanjay Chowbey, President and CEO.

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML Robust cytotoxicity observed in primary AML patient samples across key mutations (FLT3, KMT2A, NPM1, IDH1, IDH2, or TP53), reinforcing Actimab-A's potential as a mutation-agnostic backbone therapy, complementing the manageable safety profile of Actimab-A observed across prior clinical trials in over 150 AML patients NEW YORK, April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting transcriptional reprogramming as a central mechanism driving the mutation-agnostic anti-leukemic activity of Actimab-A (lintuzumab-Ac225) in acute myeloid leukemia (AML). Preclinical translational data demonstrated that lintuzumab-Ac225 delivers potent cytotoxic activity across AML models harboring common mutations, including FLT3, NPM1, KMT2A, and TP53, as well as in primary patient samples.

PITTSBURGH, April 15, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) will host its third quarter fiscal year 2026 earnings call on Wednesday, May 6, 2026. The press release and presentation will be available on the Company's website before market on May 6.